Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05587036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Rifaximin on Gut Microbiota and Emotion

StatusRecruiting
PhasePhase 2/3
Started2023-02-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 20, 2024 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-12-17
Study Status, Oversight v3
Primary completion date2024-11→2025-07
Completion date2024-12→2025-07
2024-05-07
Study Status v2
Re-verified, no change to tracked fields
2023-03-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2023-11→2024-11
Completion date2023-11→2024-12
Start dateestimated 2022-11→confirmed 2023-02-02
Study sitesdetails revised at 1 of 1 site
2022-10-17
Original filing
A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men.
Trial Details
NCT Number NCT05587036
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Conditions Healthy Volunteers, Stress, Fear
Enrollment 60 participants
Start Date 2023-02-02
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-12-20